Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization
TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.
Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age
TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.
Chronic Liver Disease Prevalence May Triple by Decade's End, New Report Projects
Driven largely by the widespread increase in diabetes and obesity, the rise in hepatic disease disparately affects minority populations and is outpacing available medical care.
Tirzepatide Approved by FDA for Chronic Weight Management in Adults
The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
NAFLD is Now MASLD: The New Nomenclature, At-a-Glance
The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.
The Liver Meeting 2023: AASLD Offers "Journey Maps" to Focused Areas of Interest
We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.
Vonoprazan, Novel Treatment for Erosive Esophagitis, Gets FDA Nod
The novel potassium-competitive acid blocker is the first new treatment approved for the potentially cancer-producing GI disease in 30 years.
Post-ED Discharge Follow-up Visit for Acute Bronchiolitis Linked to Subsequent Hospital Admission
Infants who attended a recommended follow-up clinic visit after being seen in an ED were also slightly more likely to receive medications outside of guideline recommendations.
Immune Responses to Arexvy in Adults aged 50 to 59 Years Noninferior to those in Adults aged 60 Years and Older
The comparable immune responses were observed in 50-to 59-year-olds at high risk of RSV-LRTD as well as a wider group at average risk, according to preliminary phase 3 data.
Pediatric Disability and Poverty: A Symbiotic System
Poverty is both a cause and a consequence of disability, says pediatric rehabilitation physician Dr Amy Houtrow. She explains more about the connections in this short video.
CDC Health Advisory: Nirsevimab Shortage to Last All RSV Season
The 100 mg dose prefilled syringes are in particularly short supply and while the shortage of the 50 mg dose is not as severe, supply will be limited this season.
IDWeek 2023: 8 Research Briefs for Primary Care
Get a topline look at 8 of the many studies premiered at IDWeek that have outcomes of interest to primary care clinicians.
Tirzepatide Ups Mean Weight Loss by 21% Following Intensive Lifestyle Intervention: SURMOUNT-3
Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.
FDA Accepts sBLA for Self-Administered Intranasal Influenza Vaccine from AstraZeneca
The flexibility to self administer a flu vaccine or to administer to another in a non-clinical setting could greatly expand both access and vaccine uptake.
Combination Influenza/COVID-19 Vaccine Enters Phase 3 Trial, First Participant Dosed
The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.
FDA Approves Pentavalent Meningococcal Vaccine from Pfizer for Ages 10 to 25 years
The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.
Next Generation Cologuard Outperforms FIT for CRC Detection, Shows Improved Sensitivity, Specificity
A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.
10 Top Studies from IDWeek for Primary Care, In Case you Missed Them
IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.
New Data on Alzheimer Disease Research from Biogen Planned for Release at CTAD 2023 Meeting
At the Clinical Trials on Alzheimer's Disease Meeting, October 24-28, the biotech company will update research on lecanemab, aducanumab, and an early-stage disease treatment.
Obesity, Severe Obesity Increase Risk for Breast Cancer Recurrence
In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.
AHA Defines Cardiovascular-Kidney-Metabolic Syndrome, Redefines CVD Risk, Prevention, Management
A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.
Obesity Before, During Pregnancy Key to Future Cardiovascular Risk, New Research Suggests
A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.
FDA Issues Marketing Denial Orders for 6 Vuse Alto Flavored e-Cigarette Products
The FDA cites insufficient evidence to show the products would be beneficial for adults switching to vaping from combustible tobacco products or quitting.
IDWeek 2023 Chair on Primary Care: "Central to Every Health Outcome We Have in the US..."
IDWeek chair Heather Yun, MD, observed that "primary care clinicians are out in front of all things," and that job is big and it's hard.
GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis
Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.
Heather Yun, MD, IDWeek 2023 Chair, Says Emerging Threats May be Bigger than Pathogens
IDWeek 2023 chair Yun points to climate change and other human-driven devastation of the biosphere as the global threats that will cause disease at local levels.
IDWeek 2023: Nirsevimab Efficacy Against RSV-LRTI-Associated Hospitalization is Robust Across Infant Subgroups
IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.
IDWeek 2023: Social Determinants of RSV Hospitalization in Older Adults
IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,
Investigational mRNA CMV Vaccine Ready for Phase 3 Clinical Trial, Based on Results of Phase 2 Safety, Efficacy and Dose-Finding Study
The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.